Endo Ldl Goal Less Than 55 High Risk Patients

---
name: endo-ldl-goal-less-than-55-high-risk-patients
description: Recommends LDL-C goal <55 mg/dL in patients with established ASCVD or multiple risk factors to reduce cardiovascular risk. Triggers include: patient with established ASCVD, high-risk patient needing aggressive lipid lowering, assessing LDL-C target in secondary prevention.
---

# LDL-C goal less than 55 mg/dL for patients with established cardiovascular disease or multiple risk factors

## STEP 1 — Gather Information
Collect history of established ASCVD (prior MI, ischemic stroke, coronary revascularization, peripheral arterial disease) or multiple risk factors (diabetes, hypertension, smoking, family history of premature CAD, CKD). Obtain current lipid panel (LDL-C, HDL-C, triglycerides) and assess intensity of current statin therapy.

## STEP 2 — Rule In / Rule Out
Is there established ASCVD or ≥2 major risk factors (or diabetes plus ≥1 additional risk factor)? If yes, proceed to Step 3; if no, consider standard LDL-C goal <70 mg/dL per primary prevention guidelines.

## STEP 3 — Classify or Stratify
Is the current LDL-C level ≥55 mg/dL? If yes, classification indicates need for intensification of lipid-lowering therapy; if LDL-C is already <55 mg/dL, continue current regimen and monitor.

## STEP 4 — Decide
For patients with LDL-C ≥55 mg/dL, add nonstatin LDL‑lowering therapy (ezetimibe or PCSK9 inhibitor) to maximally tolerated statin to achieve LDL-C <55 mg/dL; re‑check lipid panel in 4‑12 weeks.

## Clinical Guardrails / Mimics / Pitfalls
Do not apply the <55 mg/dL goal to patients without ASCVD or insufficient risk factors, as it may expose them to unnecessary drug‑related adverse effects. Avoid over‑intensification in frail elderly or those with limited life expectancy where harms may outweigh benefits. Monitor for statin‑associated muscle symptoms, hepatic enzyme elevations, and drug interactions when adding ezetimibe or PCSK9 inhibitors. If triglycerides are markedly elevated (>500 mg/dL), consider non‑HDL‑C or apoB as alternative targets.

## Concrete Clinical Example
A 62‑year‑old male with prior MI, type 2 diabetes, and hypertension is on atorvastatin 20 mg daily with LDL‑C 68 mg/dL. He has established ASCVD and multiple risk factors, so the LDL‑C goal is <55 mg/dL. Adding ezetimibe 10 mg daily reduces LDL‑C to 48 mg/dL, meeting the target.

**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674
> **TODO:** consider adding scripts/calc.py for the endo-ldl-goal-less-than-55-high-risk-patients calculator